Get notified of page updates

Targeted and Immunotherapies

Read about cancer treatment options listed by gene mutation, type of cancer and type of treatment.

Stay up to date on research and information

Sign Up for FORCE Newsletters
Glossary on
off

and for endometrial cancer

Targeted therapies and immunotherapies are mainly used to treat advanced or recurrent endometrial cancer. approved drugs are listed below. Clinical trials using these agents may also be available for treatment of endometrial cancer.

Immunotherapies 

Immunotherapies are cancer treatments that help the body’s immune system detect and attack cancer cells. The most common type of  immunotherapies used for endometrial cancer are called immune checkpoint inhibitor. These are most often used to treat advanced or endometrial cancer with biomarkers known as MSI-H and . People with often develop cancers with these biomarkers.

  • Jemperli (dostarlimab) is used in combination with chemotherapy as first line treatment for MSI-H or advanced endometrial cancer. 
  • Jemperli is used alone to treat MSI-H or advanced or recurrent endometrial cancer, which came back or got worse after platinum chemotherapy. 
  • Keytruda is used alone to treat MSI-H or advanced or recurrent endometrial cancer, in people whose cancer came back or got worse after previous treatment and who are not candidates for curative surgery or radiation. 
  • Keytruda is used alone to treat advanced cancers with the tumor mutational burden-High (TMB-H) that have progressed after treatment and for which there are no other treatment options.
  • Keytruda (pembrolizumab) is used to in combination with the targeted drug lenvatinib in women with advanced endometrial cancers that are not or MSI-H, usually after other treatments have been tried.

Targeted therapies

Targeted therapies are designed to attack or kill cancer cells, while sparing normal cells as much as possible. These therapies are often designed to target abnormal proteins, receptors or genes that are found in high quantities in cancer cells or the surrounding tissue.  

is still fairly new in the treatment of endometrial cancer. Currently, these agents are only prescribed if the cancer has recurred or as part of a clinical trial. Targeted therapies for endometrial cancer include:

  • Vitrakvi (larotrectinib) is approved for treatment of endometrial cancer that is or cannot be removed with surgery and has worsened with other treatments. It targets a specific genetic change called an NTRK fusion. This type of genetic change is found in a range of cancers, including a rare type of uterine cancer known as uterine sarcoma.
  • Lenvima (lenvatinib) helps block tumors from forming new blood vessels. Lenvima can be used along with the drug Keytruda to treat some advanced endometrial cancers, typically after at least one other drug treatment has been tried.
  • Afinitor (everolimus) is a type of known as an mTOR inhibitor that has been used (off label) to treat some people with advanced endometrial cancer. Afinitor does not have approval for use in endometrial cancer. 
  • Avastin (bevacizumab) helps block tumors from forming new blood vessels. Avastin does not have approval for use in endometrial cancer. 

Table of targeted and immunotherapies for endometrial cancer

Name of drug Type of agent Cancer Indication
Jemperli (dostarlimab) Immune checkpoint inhibitor
Immune checkpoint inhibitor
Recurrent or advanced endometrial cancer In combination with chemotherapy, followed by Jemperli alone to treat primary advanced or recurrent endometrial cancer that is mismatch repair deficient () or microsatellite instability-high (MSI-H) High (MSI-H) or  (
Recurrent or advanced endometrial cancer For treatment of recurrent or advanced endometrial cancer that is mismatch repair deficient () that has progressed on or following a prior platinum-containing regimen VENTANA MMR RxDx Panel
Keytruda (pembrolizumab)
 
Immune checkpoint inhibitor
 
Advanced endometrial cancer  For the treatment of MSI-H or advanced or recurrent endometrial cancer that came back or got worse after previous treatment and for which there are no other treatment options High (MSI-H) or  (
or  unresectable For the treatment of that have progressed after treatment and for which there are no other treatment options High (TMB-H)
Advanced endometrial cancer Combined with Lenvima (lenvatinib) for patients whose cancer has progressed after treatment and who are not candidates for surgery or radiation  Tumor is not MSI-H or
Lenvima
(lenvatinib)
Tyrosine kinase inhibitor Advanced endometrial cancer

Combined with pembrolizumab, for the treatment of patients whose cancer has progressed after treatment and who are not candidates for surgery or radiation 

Tumor is not MSI-H or
Vitrakvi (larotrectinib) Kinase inhibitor solid tumors For treatment in solid tumors for which there are no other treatment options NTRK fusion

Paying For Care
Paying For Care

Paying for cancer treatment

The majority of public and private health insurance plans are required to cover cancer diagnosis and treatment; copays, coinsurance and deductibles often apply. Patient costs and coverage for specific doctors, facilities or treatments may vary based on your health plan. Visit our section on Insurance and Paying for Care: Treatment  for more information, links to sample appeal letters and other resources. 

If you need information about finding an insurance plan, watch our video: Choosing Wisely: How to Pick Insurance Plans.

Some pharmaceutical companies have assistance programs that help cover the cost for their medications: 

Organizations that offer co-pay assistance:

Other resources:

  • The American Cancer Society provides information and resources on covering the cost of cancer care. Public assistance, such as Medicaid may be available if you are ineligible for other programs. 
  • Needy Meds: Assistance programs to help patients with cost of medications and other healthcare.
  • Triage Cancer offers tools and resources to help individuals cope with the financial aspects of a cancer diagnosis.

Open Clinical Trials
Open Clinical Trials

The following studies are enrolling people with advanced endometrial cancer.  

A number of other clinical trials for patients with endometrial cancer can be found here.

Last updated August 26, 2023